CLAIM #2382 · AbbVie Inc (ABBV) · 2024Q2 earnings call · Jul 25, 2024 · due Dec 31, 2024
“We also recently received a positive CHMP opinion recommending Skyrizi for the treatment of moderate to severe ulcerative colitis in Europe, with an approval decision anticipated soon.”
Roopal Thakkar · EVP, Chief Scientific Officer
PENDING
graded after results covering Dec 31, 2024 are reported
Verify independently
SEC filings for ABBV ↗ · Claim quote is verbatim from the 2024Q2 earnings call.